SCHEMBL7182129

SCHEMBL7182129

O=C(c1c(COc2ccccc2)cccc1COc1ccccc1)P(=O)(C(=O)c1c(C(F)(F)F)cccc1C(F)(F)F)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.49
MAOA P21397 1/20 0.49
ADAMTS4 O75173 1/20 0.41
MMP13 P45452 1/20 0.41
SPHK2 Q9NRA0 4/20 0.40
SPHK1 Q9NYA1 4/20 0.40
MCL1 Q07820 1/20 0.40
FFAR4 Q5NUL3 2/20 0.39
FFAR1 O14842 1/20 0.39
PTGER1 P34995 1/20 0.39
PTGER4 P35408 1/20 0.39
PTGER3 P43115 1/20 0.39
PTGER2 P43116 1/20 0.39
HPGD P15428 1/20 0.39
ALOX5 P09917 1/20 0.39
ALOX5AP P20292 1/20 0.39
KDM4E B2RXH2 2/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182509 0.85 POLQ (0.40) MAOBMAOAKDM4EKMT2ASMN1; SMN2
SCHEMBL7187675 0.81 NR4A2 (0.50) MAOBMAOAPTGER1PTGER4PTGER3
SCHEMBL7177239 0.81 MAOB (0.47) MAOBFFAR4FFAR1PTGER1PTGER4
SCHEMBL7181601 0.79 KDM4E (0.47) SPHK2SPHK1FFAR1PTGER1PTGER4
SCHEMBL7182136 0.78 KCNK3 (0.48) KDM4EKMT2A
SCHEMBL7179536 0.78 PTGER1 (0.42) MAOBFFAR4FFAR1PTGER1PTGER4
SCHEMBL7177172 0.78 NR4A2 (0.40) MAOBMAOAMCL1FFAR4FFAR1
SCHEMBL7175290 0.77 ALDH1A1 (0.39) KDM4E
SCHEMBL7182186 0.77 TYK2 (0.48)
SCHEMBL7181415 0.77 TAS2R14 (0.41) MAOBHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAOB 4189/4885MAOA 4231/4885ADAMTS4 4844/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAOB 4319/4885MAOA 4267/4885ADAMTS4 4833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.